ONYX PHARMACEUTICALS INC
Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY12 | FY11 | FY10 | FY09 | FY08 | |
|---|---|---|---|---|---|
| Revenue | $72.0M | $67.1M | $62.9M | $251.4M | $194.3M |
| Operating income | −$50.8M | −$41.3M | −$8.8M | $20.2M | −$10.4M |
| Net income | −$56.2M | −$49.2M | −$12.0M | $16.2M | $1.9M |
| Total assets | $1.35B | $1.42B | $1.35B | $1.32B | — |
| Total liabilities | — | — | — | — | — |
| Equity | $820.1M | $823.4M | $697.6M | $750.6M | $475.2M |
| EPS (diluted) | $-0.88 | $-0.78 | $0.19 | $0.27 | $0.03 |
| Shares out. | 64.1M | 63.0M | 62.9M | 62.3M | 56.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2012- Operating margin
- −70.5%
- Net margin
- −78.0%
- Return on equity
- −6.9%
- Return on assets
- −4.2%
- Return on capital (ROCE)
- −4.2%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $12.80
- Revenue growth (YoY)
- 7.3%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2012- Accruals / assets
- 12.9%high accruals
- Piotroski F-Score
- 1/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 4 warning● 1 good- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- High accruals — earnings-quality risk
- Revenue is growing year-over-year
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Cagnoni Pablo JOfficer — EVP, Global R&D and Tech Ops | Oct 1, 2013 | D | 16,257 | $125.00 |
| Wierenga WendallDirector | Oct 1, 2013 | U | 9,080 | $125.00 |
| Shema Suzanne MOfficer — EVP,GC and Corp. Secretary | Oct 1, 2013 | U | 6,468 | $125.00 |
| Wood Julianna ROfficer — VP, Public Affairs | Oct 1, 2013 | U | 9,824 | $125.00 |
| Fust Matthew KOfficer — EVP & Chief Financial Officer | Oct 1, 2013 | U | 9,153 | $125.00 |
| Foster-Cheek Kaye IOfficer — SVP, Global Human Resources | Oct 1, 2013 | U | 5,666 | $125.00 |
| Coles N AnthonyOfficer — Chairman & CEO | Oct 1, 2013 | U | 25,632 | $125.00 |
| Ringo William RDirector | Oct 1, 2013 | U | 7,737 | $125.00 |
| Grillo Lopez Antonio JDirector | Oct 1, 2013 | D | 2,100 | $125.00 |
| Lundberg MagnusDirector | Oct 1, 2013 | U | 12,116 | $125.00 |
| Torley HelenOfficer — EVP, Chief Commercial Officer | Oct 1, 2013 | U | 7,336 | $125.00 |
| Nevinny Corinne HDirector | Oct 1, 2013 | D | 2,100 | $125.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Debt acceleration / triggering event · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsOct 1, 2013
- Other material eventSep 24, 2013
- Entered a material agreement · Other material eventAug 26, 2013
- Results of operationsAug 8, 2013
- Results of operationsJul 31, 2013
- Other material eventJul 1, 2013
- Director / officer change · Shareholder voteMay 23, 2013
- Results of operationsMay 7, 2013
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.